{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-129981","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.394961+00:00","generated_at":"2026-05-29T01:53:54.440504+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Armata Pharmaceuticals Announces Phase 2 Tailwind Study Results for Inhaled AP-PA02 in NCFB Subjects","bullets":["Post-hoc analysis showed statistically significant reduction of P.a. CFUs at day 17 (P=0.05) and day 24 (P=0.015).","Approximately one-third of AP-PA02 monotherapy subjects achieved at least a 2-log CFU reduction versus none on placebo.","Inhaled AP-PA02 was well-tolerated with mild, self-limiting adverse events; one possibly related serious adverse event reported.","AP-PA02 is a novel multi-phage therapeutic for chronic Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis.","Results suggest AP-PA02 monotherapy may be as effective as combination with anti-pseudomonal antibiotics in reducing lung P.a. burden."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-129981","json":"https://secwatch.observer/filing/0001104659-24-129981.json","markdown":"https://secwatch.observer/filing/0001104659-24-129981.md","text":"https://secwatch.observer/filing/0001104659-24-129981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465924129981/0001104659-24-129981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465924129981/tm2431487d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-29T01:53:54.440504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}